Human Des(1-3)IGF-I (Receptor Grade)

 
 

Biotech Reagents Ordering >> Full Product List >>

Description:

Human Des(1-3)Insulin-like Growth Factor-I (IGF-I) is a 67 amino acid analog of human IGF-I lacking the N-terminal tripeptide Gly-Pro-Glu. Human Des(1-3)IGF-I is more potent than IGF-I in vitro and in vivo. This increased potency is due to reduced binding of human Des(1-3)IGF-I to most of the IGF binding proteins which normally inhibit the biological actions of IGF-I. Human Des(1-3)IGF-I binds to the Type 1 IGF receptor with similar affinity to full length IGF-I. This is a high quality reagent for use in studies on cell growth, IGF receptors and IGFBPs.

References:

Bagley C. et al. (1991) Biochem. Biophys. Res. Comm. 149, 398-404
Tomas F. et al. (1991) J. Endocrinol. 128, 97-105

Source:

Produced recombinantly

Purity:

> 95 % (by HPLC and N-terminal sequence analysis)

Molecular Weight:

7365 daltons – confirmed by Mass Spectrometry

N-terminal sequence analysis:

5 residues > 95 % single sequence

Biological Activity:

Type 1 IGF receptor binding assay: ED50 < 10 ng/ml
IGF binding protein assay: ED50 > 100 ng/ml
Stimulation of protein synthesis in rat L6 myoblasts: ED50 < 10 ng/ml

Endotoxin:

< 0.1 EU/µg

State and Appearance:

Lyophilized white powder
Dried from 0.1 M acetic acid and stored under dry nitrogen at a slight vacuum (-25 kPa)

Storage/Stability:

At least 2 years at 2 - 4°C (lyophilized)

Detection:

By Radioimmunoassay (RIA)

Reconstitution:

#1000: Handling of GroPep Bioreagents IGF-I, IGF-II and IGF Analogs

Related Products:

Any combination of 3 different IGF-Is and/or IGF-I analogs (all Receptor Grade)

Product Performance:
      Radioreceptor Assay:




      Protein Synthesis:




      Protein Synthesis:




      Radioreceptor Assay:



Tick box to order:

Product Codes:

DU020     20 µg    

DU100     100 µg    

DM001     1 mg    

**NOT FOR USE IN HUMANS**


Print Product Specification Sheet
Version Information: 01.02.12

 

 
 

GroPep Bioreagents: A biotechnology company serving the research, cell culture, and IGF markets.
Copyright  •  Disclaimer  •  Privacy  •  Download Acrobat Reader